Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment

Exclusion Criteria

• •All subjects:
• •Participation in another clinical trial of an investigational drug (or medical device) within 30 days of the last dose of investigational drug or 5 half-lives whichever is longer, prior to screening, or is currently participating in another trial of an investigational drug (or medical device)
• •Any signs or symptoms of acute illness at screening or Day -1
• •History or presence of clinically significant allergic, hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease
• •Patients with hepatic impairment:
• •History of liver transplantation, hepatic mass suggestive of hepatocellular carcinoma or acute liver disease
• •Screening serum ALT or AST \>5 times the upper limit of normal